Active Cancer NIHR-supported project Digestion, Kidneys & Other Organs

A phase i/ii dose-escalation and expansion study evaluating the safety, pharmacokinetics, and activity of gdc-7035 as a single agent and in combination with other anti-cancer therapies in patients with advanced solid tumors with a kras g12d mutation

Funder NIHR (part of DHSC)
Recipient organisation NIHR University College London Hospitals Biomedical Research Centre
NIHR support Recorded as supported by this research centre
Period Feb 2025 — May 2028

About this grant

This summary is based on the grant title only — the full abstract was not available.

No substantive source abstract was published for this research project funded by NIHR.

Researchers

Martin Forster (Principal Investigator)

Related Research

Grants with similar aims, by meaning.

A phase ia/ib dose-escalation and doseexpansion study evaluating the safety, pharmacokinetics, and activity of gdc-6036 as a single agent and in combination with other anti-cancer therapies in patients with advanced or metastatic solid tumors with a kras g12c mutation
A phase ia/ib dose-escalation and dose –expansion study evaluating the safety, pharmacokinetics, and activity of gdc-6036 as a single agent and in combination with other anti-cancer therapies in patients with advanced or metastatic solid tumors with a kras g12c mutation (kras g12c)
A Phase Ia/Ib Dose-Escalation And Dose-Expansion Study Evaluating The Safety, Pharmacokinetics, And Activity Of GDC-6036 As A Single Agent And In Combination With Other Anti-Cancer Therapies In Patients With Advanced Or Metastatic Solid Tumors With A KRAS G12c Mutation
A phase ib/ii, open-label, multicenter study evaluating the safety, activity, and pharmacokinetics of gdc-6036 in combination with other anti-cancer therapies in patients with previously untreated advanced or metastatic non?small cell lung cancer with a kras g12c mutation
GO45416 - A phase I/II dose escalation and expansion study evaluating the safety, pharmacokinetics, and activity of GDC-7035 as a single agent and in combination with other anti-cancer therapies in patients with advanced solid tumours with a KRAS G12D mutation

Original classification

Cancer

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.